Live feed08:05:00·52dNEWSReleasevia QuantisnowMipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%ByQuantisnow·Wall Street's wire, on your screen.APVO· Aptevo Therapeutics Inc.Health Care
